Nationwide registry for IgG4-related disease in China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to establish a nationwide cohort of patients diagnosed with IgG4-related disease (IgG4-RD) across multiple centers in China. Patients meeting the 2011 diagnostic criteria for IgG4-RD will be enrolled, and their clinical manifestations, demographic features, laboratory results, and treatment outcomes will be systematically recorded in an online database. The study seeks to enhance understanding of the disease's characteristics and improve patient management through comprehensive data collection and analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Conforming to the diagnostic criteria of IgG4-RD (2011);

Exclusion Criteria:

* Excluding other mimicing IgG4-RD, including tumors, vasculitis and sarcoidosis.

Where it's running

• Peking Union Medical College Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Yunyun Fei
• Email: feiyunyun2013@hotmail.com
• Phone: +8613681125226

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dermal priming to boost flu vaccine response in people on B cell depletion

  This study tests whether applying a topical cream with imiquimod on the skin around vaccination can boost the body’s response to the flu shot in people who are receiving B cell–depleting therapy.

  Recruiting Cambridge University Hospitals NHS Foundation Trust · Cambridge · NCT07925996

• FAPI‑74 PET/CT versus FDG PET/CT for inflammation in FUO, IgG4‑RD, and axial spondyloarthritis

  This project will test whether [18F]-AlF-FAPI-74 PET/CT finds inflammation more accurately than standard [18F]-FDG PET/CT in people with fever of unknown origin, IgG4‑related disease, or axial spondyloarthritis.

  Recruiting Phase 2/3 Universitaire Ziekenhuizen KU Leuven · Leuven · NCT07535554

• Anti-BCMA-CD19 CAR-T therapy for relapsed or refractory IgG4-related disease

  This trial will test a personalized CAR-T cell therapy that targets BCMA and CD19 in adults (18–75) whose IgG4-related disease has come back or not responded to standard treatments like steroids or rituximab.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07148791

• Comparing low- and higher-dose lenalidomide plus prednisone versus prednisone alone for active proliferative IgG4‑related disease

  This 52-week randomized trial will test whether adding 5 mg or 10 mg lenalidomide to prednisone helps adults with active proliferative IgG4‑related disease do better than prednisone alone.

  Recruiting Phase 2/3 Peking Union Medical College Hospital · Beijing · NCT07068165

• ACE1831 cell therapy for safety, effectiveness, and persistence in people with IgG4-related disease

  This trial will test ACE1831, an off-the-shelf gamma delta T cell therapy from healthy donors, to see if it is safe and helps adults with active IgG4-related disease.

  Recruiting at 11 sites Phase 1/2 Acepodia Biotech, Inc. · Atlanta, Georgia and 10 other locations · NCT07061938

• Evaluating PRG-1801 for treating difficult cases of Lupus Nephritis and IgG4-Related Disease

  This study is testing a new treatment called PRG-1801 to see if it can help adults with tough cases of Lupus Nephritis and IgG4-Related Disease feel better.

  Recruiting Early Phase 1 Tongji Hospital · Wuhan, Hubei · NCT06497387

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.